These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27659548)

  • 21. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
    Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
    Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy in elderly patients with colorectal cancer.
    Köhne CH; Folprecht G; Goldberg RM; Mitry E; Rougier P
    Oncologist; 2008 Apr; 13(4):390-402. PubMed ID: 18448553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
    Nakayama G; Ishigure K; Yokoyama H; Uehara K; Kojima H; Ishiyama A; Hayashi N; Takano N; Hattori N; Kobayashi D; Tanaka C; Hayashi M; Kanda M; Yamada S; Sugimoto H; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    BMC Cancer; 2017 Apr; 17(1):243. PubMed ID: 28376737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
    Mizushima T; Fukunaga M; Sueda T; Ikeda M; Kato T; Kim HM; Kudo T; Murata K; Nishimura J; Hata T; Matsuda C; Yamamoto H; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):81-90. PubMed ID: 28510802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
    Cubillo A; Rodriguez-Pascual J; López-Ríos F; Plaza C; García E; Álvarez R; de Vicente E; Quijano Y; Hernando O; Rubio C; Perea S; Sanchez G; Hidalgo M
    Am J Clin Oncol; 2016 Jun; 39(3):236-42. PubMed ID: 24517959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Systemic treatment of colorectal cancers--factual standards and perspectives].
    Miron L
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):752-8. PubMed ID: 14756014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
    Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
    Zhao Z; Pelletier E; Barber B; Bhosle M; Wang S; Gao S; Klingman D
    Curr Med Res Opin; 2012 Feb; 28(2):221-9. PubMed ID: 22171947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.
    Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D
    Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
    Haller DG; Rothenberg ML; Wong AO; Koralewski PM; Miller WH; Bodoky G; Habboubi N; Garay C; Olivatto LO
    J Clin Oncol; 2008 Oct; 26(28):4544-50. PubMed ID: 18824706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.